For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Davunetide
Cognitivephase_2_3

Davunetide

NAP
Cognitive
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Cognitive
Evidence grade
B
PubMed records
102
Female-tagged
24
Sex-analysis
4
CAS
—
B
Evidence grade B, Phase 2/3 human trial evidence across 102 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Davunetide, also known as NAP, is an eight-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP). It was developed specifically as a research material for studying neuroprotection at the cytoskeletal level, which distinguishes it from broadly acting neuroactive compounds.

In preclinical models, davunetide has been studied for its association with microtubule stabilization and tau-related signaling, mechanisms relevant to neurodegeneration research. Investigators examining cytoskeletal integrity and neuroprotective pathways have used it as a defined research material.

What makes davunetide a useful catalog entry is the specificity of its studied mechanism, a defined structural target rather than a diffuse effect, which supports isolated study. Whether these mechanisms translate the same way across female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Davunetide (NAP) is a neuroprotective peptide studied for tauopathies; a large Phase 2/3 trial in progressive supranuclear palsy failed to meet its endpoints. Trials enrolled women, but published results were not analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
No study examined cognitive endpoints across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data from the trial program.
Hormonal interactions
Unstudied
No controlled data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific analyses.
Sex differences
Unstudied
Trials enrolled women, but published results were not analyzed by sex.

Mechanism

An octapeptide fragment of activity-dependent neuroprotective protein proposed to stabilize microtubules and reduce tau pathology.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Intranasal dosing was used in the Phase 2/3 program; investigational, no approved dose.
Routesintranasal
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nasal discomfortgenerally well tolerated in trials

Davunetide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Davunetide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Davunetide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Davunetide?

Davunetide, also known as NAP, is a research compound in our cognitive category. Davunetide (NAP) is a neuroprotective peptide studied for tauopathies; a large Phase 2/3 trial in progressive supranuclear palsy failed to meet its endpoints.

Is Davunetide studied in women?

Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Davunetide been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data from the trial program. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Davunetide have, and why?

Davunetide carries evidence grade B. Phase 2/3 human trial evidence across 102 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Davunetide?

No. A female-specific dose for Davunetide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Davunetide administered in research?

In the published literature, Davunetide is administered via intranasal. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Davunetide?

Effects reported in the research literature include nasal discomfort, generally well tolerated in trials. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Davunetide be stored and handled?

Davunetide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Davunetide for research?

Davunetide is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Davunetide isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

23971871 · 40185278

Related peptides

Arginine VasopressinA
Arginine Vasopressin: of 12,241 PubMed records, 4,072 are tagged as including female subjects and 100 carry a sex-analysis tag.
BromantaneC
Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag.
CerebrolysinB
Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag.
DihexaD
Dihexa: of 17 PubMed records, 0 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.